Bayer Wants Aspirin CVD Screening Tool To Reach 100m In US As It Plans International Roll-Out 

 
• By David Ridley

Bayer hopes its innovative Aspirin-branded Heart Risk Assessment Tool will reach 100m in the US and its planning an international roll-out, the firm's general manager and vice president of pain and cardio, US, Kelly Fanning tells HBW Insight in an exclusive Q&A. Fanning also explains what Bayer is doing to manage the current surge in demand for Aspirin in the US, UK and Europe.

Cardiovascular

Consumers in the Middle East and Latin America who think they might be at risk of cardiovascular disease (CVD) will soon be able to access Bayer’s innovative Heart Risk Assessment Tool.

Speaking exclusively to HBW Insight, Bayer Consumer Health US’s Kelly Fanning, general manager and vice president of pain and cardio, reveals that the Aspirin-branded tool

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from International

More from Geography